IP Library Granted Patent US 11,162,105
Granted Patent B2
US 11,162,105 · App. 16/460,025 · Granted Nov 2, 2021

Engineered purine nucleoside phosphorylase variant enzymes

Inventors: Scott J. Novick (Palo Alto, CA); Nikki Dellas (Mountain View, CA); Vesna Mitchell (Santa Clara, CA); Da Duan (Newark, CA); Jovana Nazor (Milpitas, CA); Oscar Alvizo (Fremont, CA); Auric Anthony Sowell-Kantz (Fairfax, CA); Jeffrey C. Moore (Westfield, NJ); Mark Huffman (Rahway, NJ); Agustina Rodriguez-Granillo (Rahway, NJ); Deeptak Verma (Rahway, NJ); Nicholas M. Marshall (Rahway, NJ); Jay Russell (Rahway, NJ); Keith A. Canada (Freehold, NJ)
Assignee: Codexis, Inc.
C12N15/63C12Y204/02001
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 11,162,105
App. No.
16/460,025
Granted
Nov 2, 2021
Kind
B2
Abstract

The present invention provides engineered purine nucleoside phosphorylase (PNP) enzymes, polypeptides having PNP activity, and polynucleotides encoding these enzymes, as well as vectors and host cells comprising these polynucleotides and polypeptides. Methods for producing PNP enzymes are also provided. The present invention further provides compositions comprising the PNP enzymes and methods of using the engineered PNP enzymes. The present invention finds particular use in the production of pharmaceutical compounds.

Claims (6)

1. An engineered purine nucleoside phosphorylase comprising a polypeptide sequence having at least 85% sequence identity to SEQ ID NO:2, 6, and/or 126, wherein the polypeptide sequence of said engineered purine nucleoside phosphorylase comprises a substitution at position 65 and wherein the amino acid positions of said polypeptide sequence are numbered with reference to SEQ ID NO: 2, 6, and/or 126, and wherein said engineered purine nucleoside phosphorylase

comprises improved activity on the substrate of compound 3 as compared to wild-type E. coli purine nucleoside phosphorylase.

2. The engineered purine nucleoside phosphorylase of claim 1 , wherein said engineered purine nucleoside phosphorylase comprises a polypeptide sequence that is at least 85% identical to the sequence of at least one engineered purine nucleoside phosphorylase variant set forth in the sequences of SEQ ID NOs: 684, 892, 894, 896, 898 and 900.

3. The engineered purine nucleoside phosphorylase of claim 1 , wherein said engineered purine nucleoside phosphorylase comprises a polypeptide sequence set forth in at least one of the sequences of SEQ ID NOs: 684, 892, 894, 896, 898 and 900.

4. The engineered purine nucleoside phosphorylase of claim 1 wherein said engineered purine nucleoside phosphorylase is purified.

5. A composition comprising the engineered purine nucleoside phosphorylase of claim 1 .

Assignments (2)
SECURITY INTEREST Recorded Feb 15, 2024
From: CODEXIS, INC.
To: INNOVATUS LIFE SCIENCES LENDING FUND I, LP, AS COLLATERAL AGENT
Reel/Frame 066600/0650 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Oct 2, 2019
From: NOVICK, SCOTT J.; DELLAS, NIKKI; MITCHELL, VESNA; DUAN, DA; NAZOR, JOVANA; ALVIZO, OSCAR; SOWELL-KANTZ, AURIC ANTHONY
To: CODEXIS, INC.
Reel/Frame 050606/0577 →
Continuity (3)
Provisional Application 62695507 · Jul 9, 2018
Provisional Application 62822263 · Mar 22, 2019
Related Publication 20200010834A1 · Jan 9, 2020